Overview

* Nkarta ( NKTX ) reports Q3 net loss of $21.7 mln

* Company has $316.5 mln in cash, funding operations into 2029

* NKX019 clinical program progresses with streamlined enrollment and promising B-cell depletion

Outlook

* Nkarta ( NKTX ) expects cash reserves to fund operations into 2029

* Company plans to present NKX019 data at a medical conference in 2026

* Nkarta ( NKTX ) streamlines enrollment for Ntrust-1 and Ntrust-2 trials

Result Drivers

* RESEARCH AND DEVELOPMENT: R&D expenses were $20.2 million for the third quarter of 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.29

Q3 Net -$21.72

Income mln

Q3 Basic -$0.29

EPS

Q3 Cash $316.50

& mln

Investme

nts

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Nkarta Inc ( NKTX ) is $12.00, about 83.7% above its November 7 closing price of $1.96

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)